Evidence map›Paper›PMID 41355981›Full record

ArticleFrontiers in cellular and infection microbiology2025

Pathogen spectrum, clinical traits and exploration of mortality outcome-improving medication regimens in coinfection patients with severe fever with thrombocytopenia syndrome: a multicenter cohort study.

Zibo Fan, Lianhe Lu, Ling Lin, Jianping Duan, Qun Li, Chuanyun Zhao, Zhenghua Zhao, Yuanni Liu, Yong Zhou, Wei Zhou and 3 more

Abstract readClinical StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zibo Fan *National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Lianhe Lu *National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Ling Lin *Yantai Qishan Hospital, Yantai, Shandong, China.
Jianping Duan *Qingdao Infectious Disease Hospital, Qingdao, Shandong, China.
Qun LiNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Chuanyun ZhaoTaian City Central Hospital, Taian, Shandong, China.
Zhenghua ZhaoTaian City Central Hospital, Taian, Shandong, China.
Yuanni LiuYantai Qishan Hospital, Yantai, Shandong, China.
Yong ZhouQingdao Infectious Disease Hospital, Qingdao, Shandong, China.
Wei ZhouDalian Public Health Clinical Center, Dalian, Liaoning, China.
Yi ShenDandong Infectious Disease Hospital, Dandong, Liaoning, China.
Zhihai ChenNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Wei ZhangNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Using a multicenter clinical data, this study aimed to systematically analyze the clinical characteristics, pathogen spectrum, and independent risk/protective factors for coinfection in SFTS patients; additionally, it sought to explore optimal therapeutic regimens to reduce the case fatality rate of SFTS patients with coinfection. Methods: Clinical data of 1,675 patients with SFTS who were hospitalized for the first time, collected from 6 institutions between May 2011 and November 2024, were included and analyzed. Results: The coinfection group had a significantly higher case fatality rate (24.3% vs. 6.7%, Conclusion: This study found a high proportion of SFTS patients with coinfection, which significantly worsens their clinical prognosis. SFTS currently has no specific therapy; clinical treatment focuses on symptomatic and supportive care, with strict standardization for antibiotics and antifungal use, and attention to patients' nutritional support. Albumin is a key protective factor associated with a lower risk of coinfection in SFTS patients; combined use of human albumin and corticosteroids was associated with a further trend toward better clinical prognosis in coinfected patients.

Indexed as

CoinfectionSevere Fever with Thrombocytopenia SyndromeAdrenal Cortex HormonesAdultAgedAged, 80 and overBacterial InfectionsCohort StudiesFemaleHumansMaleMiddle AgedMycosesPhlebovirusPrognosisRetrospective StudiesAdrenal Cortex Hormonesbacteriacase fatality ratecoinfectionfungussevere fever with thrombocytopenia syndrome

Identifiers

PMID41355981
PMCPMC12678257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.